The companies said that the new collaboration will support the development program of therapies that caters to multiple rare diseases such as, lysosomal storage diseases (LSDs).
Synageva R&D head and chief medical officer Anthony Quinn said that this collaboration, which combines Synageva’s proprietary compounds and technology with to-BBB’s expertise in CNS delivery, provides Synageva with an opportunity to extend the therapeutic benefits of their pipeline products targeting rare diseases with CNS manifestations.